InsiderTrades.com logo
Urgent Nvidia Warning
From Altimetry   |   Ad
Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
Click here to access…

John Dyett Biography and Net Worth

Director of Femasys
  • Phone
  • Email
  • Website


John Dyett has served as a member of our board of directors since January 2017. Mr. Dyett has served as the Co-CEO of Salem Partners, LLC since 1997 and Salem Partners Wealth Management, LLC since 2004. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Mr. Dyett helped launch ZS Pharma, Inc., a specialty pharmaceutical company. ZS Pharma, Inc. completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Mr. Dyett was also a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett previously served on the board of directors of Sierra Total Return Fund from 2016 to 2020. Mr. Dyett also serves on the board of directors of Medley Management and OncoNano Medicine. Mr. Dyett is a graduate of Harvard College with BA in Government and Economics.

How do I contact John Dyett?

The corporate mailing address for Mr. Dyett and other Femasys executives is , , . Femasys can also be reached via phone at 770-500-3910 and via email at [email protected]. Learn More on John Dyett's contact information.

Has John Dyett been buying or selling shares of Femasys?

John Dyett has not been actively trading shares of Femasys during the last quarter. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.

John Dyett Insider Trading History at Femasys

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/23/2021Buy53,500$12.93$691,755.00
See Full Table

John Dyett Buying and Selling Activity at Femasys

This chart shows John Dyett's buying and selling at Femasys by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Femasys Company Overview

Femasys logo
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Read More

Today's Range

Now: $1.24
Low: $1.22
High: $1.33

50 Day Range

MA: $1.61
Low: $1.27
High: $2.22

2 Week Range

Now: $1.24
Low: $0.25
High: $4.75

Volume

283,856 shs

Average Volume

256,984 shs

Market Capitalization

$27.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Urgent Nvidia Warning
From Altimetry   |   Ad
Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.
Click here to access…